Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

Blood Transfusion Risk Factors and Cell Saver Impact in Pediatric Scoliosis Surgery

NCT: NCT07661589 · RECRUITING

NCT IDNCT07661589
StatusRECRUITING
Start Date2023-04-01
Completion2026-12-31
SponsorMehdi Trifa (OTHER)
First posted
Last updated

Brief Summary

Spine surgery for scoliosis correction in pediatric patients is a major procedure associated with a high risk of perioperative blood loss. Homologous blood transfusion carries inherent risks, including immunological reactions, infections, and increased healthcare costs. Identifying high-risk patients is crucial to optimize blood conservation strategies. This retrospective study aims to identify preoperative and intraoperative risk factors associated with homologous red blood cell (RBC) transfusion and to evaluate the quantitative impact of Cell Saver volume reinfusion on reducing homologous transfusion requirements.

Frequently Asked Questions

What is Blood Transfusion Risk Factors and Cell Saver Impact in Pediatric Scoliosis Surgery?

Blood Transfusion Risk Factors and Cell Saver Impact in Pediatric Scoliosis Surgery is a clinical trial registered under NCT07661589. Current status: RECRUITING.

What is the status of NCT07661589?

The current status of NCT07661589 (Blood Transfusion Risk Factors and Cell Saver Impact in Pediatric Scoliosis Surgery) is: RECRUITING.

When did Blood Transfusion Risk Factors and Cell Saver Impact in Pediatric Scoliosis Surgery start?

Blood Transfusion Risk Factors and Cell Saver Impact in Pediatric Scoliosis Surgery started on 2023-04-01.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.